FDA Drops Guide for Testing Wrist-Worn Blood Pressure Gadgets
Published Date: 1/23/2026
Notice
Summary
The FDA just dropped a draft guide for companies making cuffless blood pressure devices, showing how to test and prove their gadgets work well. This affects device makers aiming to get FDA approval and helps make sure your new tech is safe and accurate. Comments on this draft are open until March 24, 2026, so get your thoughts in before then!
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
Draft testing guidance for cuffless BP devices
The FDA released a draft guidance titled "Cuffless Non-invasive Blood Pressure Measuring Devices--Clinical Performance Testing and Evaluation" that gives recommendations for clinical performance testing and evaluation to support premarket submissions for cuffless blood pressure measuring devices. The draft is not final and is not for implementation at this time.
Comment opportunity and deadline
Stakeholders may submit electronic or written comments on the draft guidance; comments must be submitted by March 24, 2026 for the Agency to consider them before it begins work on the final guidance. The docket number for comments is FDA-2025-D-0851 and submissions go through Regulations.gov or by mail to the Dockets Management Staff.
No new paperwork collection required
The draft guidance states it contains no new collection of information under the Paperwork Reduction Act and instead refers to previously approved FDA collections with OMB control numbers 0910-0120, 0910-0844, 0910-0756, and 0910-0485. These existing approvals cover premarket notification, De Novo classification, Q-submissions, and medical device labeling/UDI respectively.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
2026-12245 — Authorization of Emergency Use for Two Animal Drugs for the Prevention and Treatment of New World Screwworm; Availability
The FDA just gave the green light for two new animal drugs to fight the nasty New World screwworm, a bug that harms cattle, horses, pigs, and even exotic animals. These emergency approvals started in April 2026 to help protect U.S. livestock and wildlife quickly. Farmers, vets, and animal lovers can now use these treatments to stop infestations and keep animals safe without delay.
2026-12237 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.
Previous / Next Documents
Previous: 2026-01287 — Agency Information Collection Activities; Comment Request; Work Opportunity Tax Credit
The Department of Labor wants your thoughts on updating the paperwork for the Work Opportunity Tax Credit (WOTC), a program that helps employers save money when hiring people who face job challenges. This update aims to make the process easier and less time-consuming for everyone involved. If you have ideas or concerns, send them in by March 24, 2026—because your input can shape how this tax credit works!
Next: 2026-01289 — 60-Day Notice of Proposed Information Collection: Section 8 Renewal Policy Guidebook
HUD wants to update how it collects info for renewing Section 8 housing contracts, which affects landlords and housing agencies. They’re asking for public feedback by March 24, 2026, to make sure the process is clear and fair. These changes could impact paperwork but aim to keep affordable housing running smoothly without extra costs.